Brief: Pliant Therapeutics Announces Interim Data From PLN-101095
04/12/2025 12:39
Dec 4 (Reuters) - Pliant Therapeutics Inc PLRX.O: PLIANT THERAPEUTICS ANNOUNCES INTERIM DATA FROM PLN-101095 IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR-REFRACTORY ADVANCED SOLID TUMORS PLIANT THERAPEUTICS INC: TO ACCELERATE DEVELOPMENT OF PLN-101095 WITH INITIATION OF A PHASE 1B EXPANSION TRIAL IN 2026 Source text: ID:nGNX1plmDL Further company coverage: PLRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pliant Therapeutics
See all newsBrief: Pliant Therapeutics Announces Presentations At The 2026 Annual Meeting
Brief: Pliant Therapeutics Appoints David Raben, M.D., As Chief Medical Officer
RCS - Redx Pharma Limited - Redx Announces Final Audited Results
RCS - Redx Pharma Limited - Close of Series A; Strengthened Board Composition
U.S. STOCKS ON THE MOVE-Gold miners, Weave Communications, Amylyx Pharmaceuticals